CDX-1135
Phase 1Small molecule
CDX-1135 is one of 6 small molecule programs targeting Dense Deposit Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Dense Deposit Disease
#DrugCompanyPhaseTrials
1Fabhalta
NovartisApproved
Empaveli
Apellis PharmaceuticalsApproved
Soliris
AstraZenecaPhase 1
OMS721
OOmeros Corporation
Phase 2
Sulodexide
KKeryx Biopharmaceuticals
Phase 1
CDX-1135
CCelldex Therapeutics
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CDX-1135. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCelldex Therapeutics